PV Reporter

09/02/2026

🩸 September is Blood Cancer Awareness Month.

This cartoon shows red blood cells “gone wild,” a playful way to highlight a serious condition: polycythemia vera (PV).

In PV, the bone marrow produces too many red blood cells and sometimes platelets and white blood cells. This can thicken the blood while raising the risk of clots, strokes, or other dangerous complications.

👉 Here is an informative article on Blood Cancer Awareness Month for MPNs and more trusted resources:

https://pvreporter.com/september-blood-cancer-awareness-month-mpns/

Feel free to share this post with your network.
Like and follow PV Reporter for more resources and updates on MPNs.

09/01/2026

An exciting new chapter in polycythemia vera treatment begins.

The FDA has approved MIMRYLO™ (rusfertide), the first hepcidin mimetic for erythrocytosis in adults with PV.

For patients struggling with uncontrolled hematocrit and repeated phlebotomies, this approval brings a completely new treatment approach.

Our detailed report explains how MIMRYLO works, the VERIFY trial results, safety information, and questions for patients to ask their hematologists.

Check it out and feel free to share:

FDA approved Mimrylo (rusfertide) on Aug. 28, 2026, for erythrocytosis in adults with PV. Questions to ask your MPN specialist, trial results, side effects, etc.

08/31/2026

🗞 Great news for ET community!

FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia. We will have more details coming soon.

08/30/2026

Ever wondered how doctors actually see inside you? This side-by-side comparison shows the incredible difference between X-ray, CT, and MRI scans. I thought this was a cool depiction. Which one did you have recently?

08/29/2026

📰Big news for the PV community: the FDA has approved MIMRYLO™ (rusfertide), a first-in-class hepcidin mimetic therapy for adults with polycythemia vera!

A detailed article on what this means for patients and the PV treatment landscape is coming soon! Stay tuned on pvreporter.com for the latest MPN news updates.

08/28/2026

Blast from the Past: Celebrating PV Reporter’s 13-year anniversary since launching in Aug. 2013! 🎉

What began as a simple idea has grown into a trusted hub for MPN research, education, patient stories, and connection. PV Reporter has become my life’s passion, and every article, resource, and interview has been part of that journey.

Thank you to our loyal readers, supporters, and amazing sponsors for helping us empower the MPN community and reach the newly diagnosed. 💙

Here’s to another year of service and the joy of helping others. https://www.pvreporter.com/

08/25/2026

Six-Month Ruxolitinib Response May Predict Long-Term PV Outcomes

A new prognostic model uses 6-month ruxolitinib response to identify patients with polycythaemia vera at risk of poorer long-term outcomes.

08/15/2026

Have a great weekend, y’all! Wishing everyone perfect counts and improving health. ❤️

08/14/2026

The FDA has approved BESREMi® for adults with essential thrombocythemia (ET).

New 2-year SURPASS-ET data: high-risk ET patients who started ropeginterferon earlier had 76.9% progression-free survival at 24 months, compared to 43.1% for those whose treatment was delayed.

Two-year SURPASS-ET results suggest earlier ropeginterferon treatment may improve disease control in high-risk essential thrombocythemia.